Demographics and baseline clinical characteristics of patients with RA who received tocilizumab at any time during the blinded period or open-label extension of the tocilizumab study
| Tocilizumab (n = 143) | |
| Demographics | |
| Age, years (SD) | 54.3 (11.1) |
| No of men/no of women | 34/109 |
| Clinical characteristics | |
| RA duration, years (SD) | 9.9 (8.4) |
| No of failed DMARD, mean (range) | 4.5 (1–11) |
| Functional class,* I/II/III/IV | 10/93/40/0 |
| RA stage,* I/II/III/IV | 3/34/56/50 |
| Tender joint count, 0–49 scale (SD) | 20.3 (10.3) |
| Swollen joint count, 0–46 scale (SD) | 14.5 (8.7) |
| ESR, mm/h (SD) | 68.7 (29.9) |
| CRP, mg/dl (SD) | 4.7 (3.3) |
| DAS28 (SD) | 6.7 (1.0) |
Values are mean (SD) unless stated otherwise. The data were calculated from the baseline of the double-blind trial (4 mg/kg group, 8 mg/kg group) and from the extension trial (placebo group). *Rheumatoid arthritis (RA) functional status determined by American College of Rheumatology criteria. RA stage determined by Steinbrocker’s criteria. CRP, C-reactive protein; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate.